YARWNasdaqPharmaceutical PreparationsFiscal year ends December 31
Yarrow Bioscience, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026
$19.98+1.67 (+9.12%)
Close on Oct 19, 2026
- Market cap
- $17.14M
- P/E (TTM)
- –
- Dividend yield
- –
Share price
+$1.07 (+5.66%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.EarningsEx-dividendSplit
Yarrow Bioscience, Inc. grew revenue 13.8% to $570.00K over fiscal 2025. Free cash flow was -$33.12M.
Revenue
$570.00K
+13.8% vs. a year earlier
Operating income
-$29.75M
FY2025
Free cash flow
-$33.12M
FY2025
EPS, diluted
-$31.00
FY2025
Key statistics
Valuation at the latest close; fundamentals over fiscal 2025, balances at Jun 30, 2026
Valuation
- Market cap
- $17.14M
- P/E ratio
- –
- Price to sales
- 30.08
- Price to book
- 0.78
- Dividend yield
- –
- Free cash flow yield
- -193.22%
Fundamentals
- Revenue
- $570.00K
- Net income
- -$26.48M
- EPS, diluted
- -$31.00
- Free cash flow
- -$33.12M
- Book value per share
- $25.71
- Diluted shares
- 1M
Twelve years at a glance
Fiscal years 2014 to 2025, USD
Revenue
$570.00K+13.8% YoY
Gross profit
–
Operating income
-$29.75M
Net income
-$26.48M
EPS, diluted
-$31.00
Free cash flow
-$33.12M
Reported period